(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
-3.98% $ 1.690
Live Chart Being Loaded With Signals
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments...
Stats | |
---|---|
Tagesvolumen | 71 246 |
Durchschnittsvolumen | 62 666 |
Marktkapitalisierung | 182.98M |
EPS | $-0.0192 ( Q4 | 2023-12-31 ) |
Nächstes Ertragsdatum | ( $0 ) 2024-08-19 |
Last Dividend | $0.00500 ( 2023-09-01 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-33.80 (Sector) 0 (Industry) 0 |
ATR14 | $0.0290 (1.72%) |
Cyclopharm Ltd Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Cyclopharm Ltd Finanzdaten
Annual | 2023 |
Umsatz: | $27.14M |
Bruttogewinn: | $4.50M (16.57 %) |
EPS: | $-0.0507 |
FY | 2023 |
Umsatz: | $27.14M |
Bruttogewinn: | $4.50M (16.57 %) |
EPS: | $-0.0507 |
FY | 2022 |
Umsatz: | $23.22M |
Bruttogewinn: | $5.94M (25.58 %) |
EPS: | $-0.0717 |
FY | 2021 |
Umsatz: | $17.70M |
Bruttogewinn: | $12.66M (71.52 %) |
EPS: | $-0.0658 |
Financial Reports:
No articles found.
Cyclopharm Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.00500 (N/A) |
$0 (N/A) |
$0.00500 (N/A) |
$0 (N/A) |
$0.00500 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.00496 | 2015-10-02 |
Last Dividend | $0.00500 | 2023-09-01 |
Next Dividend | $0 | N/A |
Payout Date | 2023-09-11 | |
Next Payout Date | N/A | |
# dividends | 17 | -- |
Total Paid Out | $0.0848 | -- |
Avg. Dividend % Per Year | 0.45% | -- |
Score | 1.35 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2015 | $0.00496 | 1.79% |
2016 | $0.00992 | 1.92% |
2017 | $0.00996 | 1.10% |
2018 | $0.0100 | 1.00% |
2019 | $0.0100 | 0.93% |
2020 | $0.0100 | 0.82% |
2021 | $0.0100 | 0.39% |
2022 | $0.0100 | 0.61% |
2023 | $0.0100 | 0.85% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
01 Sep 2023 | $0.00500 | 30 Nov -0001 | 04 Sep 2023 | 11 Sep 2023 |
27 Mar 2023 | $0.00500 | 30 Nov -0001 | 28 Mar 2023 | 04 Apr 2023 |
02 Sep 2022 | $0.00500 | 30 Nov -0001 | 05 Sep 2022 | 12 Sep 2022 |
04 Apr 2022 | $0.00500 | 30 Nov -0001 | 05 Apr 2022 | 12 Apr 2022 |
03 Sep 2021 | $0.00500 | 30 Nov -0001 | 06 Sep 2021 | 13 Sep 2021 |
01 Apr 2021 | $0.00500 | 30 Nov -0001 | 06 Apr 2021 | 13 Apr 2021 |
04 Sep 2020 | $0.00500 | 25 Aug 2020 | 07 Sep 2020 | 14 Sep 2020 |
30 Mar 2020 | $0.00500 | 26 Feb 2020 | 31 Mar 2020 | 07 Apr 2020 |
06 Sep 2019 | $0.00500 | 22 Aug 2019 | 09 Sep 2019 | 16 Sep 2019 |
05 Apr 2019 | $0.00500 | 27 Feb 2019 | 08 Apr 2019 | 15 Apr 2019 |
07 Sep 2018 | $0.00500 | 23 Aug 2018 | 10 Sep 2018 | 17 Sep 2018 |
06 Apr 2018 | $0.00500 | 26 Feb 2018 | 09 Apr 2018 | 16 Apr 2018 |
01 Sep 2017 | $0.00500 | 28 Aug 2017 | 04 Sep 2017 | 11 Sep 2017 |
31 Mar 2017 | $0.00496 | 22 Feb 2017 | 03 Apr 2017 | 10 Apr 2017 |
02 Sep 2016 | $0.00496 | 19 Aug 2016 | 05 Sep 2016 | 12 Sep 2016 |
11 Apr 2016 | $0.00496 | 24 Feb 2016 | 12 Apr 2016 | 19 Apr 2016 |
02 Oct 2015 | $0.00496 | 26 Aug 2015 | 07 Oct 2015 | 14 Oct 2015 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
EZL.AX | Dividend Royal | 2024-02-02 | Semi-Annually | 24 | 11.64% | 8.24 |
GRR.AX | Dividend Royal | 2024-03-12 | Semi-Annually | 14 | 11.88% | 7.99 |
RKN.AX | Dividend Royal | 2023-08-31 | Annually | 22 | 15.73% | 7.24 |
TWR.AX | Dividend King | 2024-06-12 | Annually | 25 | 5.98% | 7.21 |
YAL.AX | Dividend Royal | 2024-03-12 | Annually | 7 | 12.76% | 7.18 |
SHM.AX | Dividend Royal | 2024-03-14 | Semi-Annually | 9 | 14.97% | 7.14 |
HZN.AX | Dividend Royal | 2024-04-18 | Semi-Annually | 4 | 18.99% | 7.06 |
BHP.AX | Dividend Royal | 2024-03-07 | Semi-Annually | 37 | 6.46% | 6.97 |
CDD.AX | Ex Dividend King | 2024-05-24 | Annually | 21 | 91.43% | 6.79 |
KSL.AX | Dividend Royal | 2024-03-05 | Semi-Annually | 9 | 9.58% | 6.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.178 | 1.500 | -3.57 | -5.35 | [0 - 0.5] |
returnOnAssetsTTM | -0.102 | 1.200 | -3.41 | -4.10 | [0 - 0.3] |
returnOnEquityTTM | -0.140 | 1.500 | -2.67 | -4.00 | [0.1 - 1] |
payoutRatioTTM | -0.188 | -1.000 | -1.882 | 1.882 | [0 - 1] |
currentRatioTTM | 3.48 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.26 | 0.800 | 1.391 | 1.113 | [0.8 - 2.5] |
cashRatioTTM | 1.353 | 1.500 | 3.60 | 5.39 | [0.2 - 2] |
debtRatioTTM | 0.0921 | -1.500 | 8.47 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -44.83 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.0765 | 2.00 | -0.0255 | -0.0510 | [0 - 30] |
freeCashFlowPerShareTTM | -0.0822 | 2.00 | -0.0411 | -0.0822 | [0 - 20] |
debtEquityRatioTTM | 0.131 | -1.500 | 9.48 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.131 | 1.000 | -1.147 | -1.147 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.368 | 1.000 | -9.35 | -9.35 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.703 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.574 | 0.800 | 9.51 | 7.61 | [0.5 - 2] |
Total Score | -0.485 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -34.23 | 1.000 | -3.56 | 0 | [1 - 100] |
returnOnEquityTTM | -0.140 | 2.50 | -1.714 | -4.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.0822 | 2.00 | -0.0274 | -0.0822 | [0 - 30] |
dividendYielPercentageTTM | 0.292 | 1.500 | 2.69 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.0765 | 2.00 | -0.0255 | -0.0510 | [0 - 30] |
payoutRatioTTM | -0.188 | 1.500 | -1.882 | 1.882 | [0 - 1] |
pegRatioTTM | -1.878 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.273 | 1.000 | -9.33 | 0 | [0.1 - 0.5] |
Total Score | -2.61 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.